STOCKS TELEGRAPH

Tag: QLGN stock

  • Qualigen Therapeutics Soars Ahead of Key Developments

    Qualigen Therapeutics Soars Ahead of Key Developments

    Qualigen Therapeutics, Inc. (NASDAQ: QLGN) experienced a significant surge on Wednesday, with its stock rising nearly 6% during regular trading hours. This momentum continued into the afterhours session, where the stock skyrocketed by over 48%, driven by market reactions to its recent earnings report and ongoing developments. This dramatic increase positions Qualigen Therapeutics as a notable player to watch ahead of the 4th of July holiday.

    Qualigen Overview and Recent Performance

    Qualigen Therapeutics is a biotechnology firm dedicated to developing treatments for cancer and infectious diseases. Its cancer therapeutics pipeline features promising candidates such as ALAN (AS1411-GNP), RAS-F3, and STARS. ALAN is a DNA-coated gold nanoparticle drug targeting various cancers with minimal side effects. RAS-F3 aims to inhibit RAS oncogene protein-protein interactions, crucial in preventing tumor formation in cancers like pancreatic, colorectal, and lung.
    Despite the promising pipeline, the company’s financial performance for the recent quarter reported an earnings per share (EPS) of -35 cents, with no revenue recorded. However, it wasn’t the financial results that fueled the afterhours rally. Investors are particularly optimistic about the company’s upcoming developments and the absence of delisting concerns until at least July 16th.

    Market Reactions and Investor Sentiment

    The market’s enthusiasm for Qualigen Therapeutics is not solely based on its earnings report. A significant driver is the upcoming July 16th hearing date, which means the stock won’t face immediate delisting threats. This period of stability has encouraged bullish sentiment, especially with potential tumor treatment news expected soon. The afterhours surge is also attributed to the anticipation of higher trading volumes and prices once the market reopens.

    Investors who missed the afterhours spike are likely to be eager to enter the market during the early trading hours on Friday, from 4 AM to 7 AM. The unusual volume and heightened interest in Qualigen Therapeutics make it a stock worth watching closely, as traders anticipate further gains driven by speculative buying and potential positive news.

    Conclusion

    Qualigen Therapeutics’ impressive afterhours performance highlights the market’s anticipation of key developments and stability in its stock status. With potential tumor treatment news and no immediate delisting concerns, the company has captured significant investor attention. As trading resumes, the focus will be on how these factors influence the stock’s trajectory, making Qualigen Therapeutics a compelling story in the biotech sector.

  • Here’s the Reason Why Qualigen, Inc. (QLGN) Stock is on a Boom

    Here’s the Reason Why Qualigen, Inc. (QLGN) Stock is on a Boom

    Qualigen, Inc. (QLGN), a biotechnology company, has soared 108.80% in aftermarket trading session. Consequently, QLGN stock is trading at $2.61 at the time of the writing. On Monday, QLGN closed the day at $1.25 after surging 25.62% during regular trading hours. The constant surge could be attributed to the strong quarterly results.

    Why QLGN Surging?

    On 15th November, QLGN released the financial results for the third quarter of the fiscal year 2021. The quarter ended on 30th September 2021. The company generated total revenue of $1.15 million during the quarter against $0.83 million for the same period of 2020. The total expenses bore by the company during the three months were $5.96 million against $4.55 million for the same period of 2020. The net loss suffered by the company during the period was $2.85 million (or $0.10 per basic and diluted share) against $8.11 million (or $0.41 per basic and diluted share) for the same period of 2020. The company had cash and cash equivalents of $12.31 million on 30th September 2021.

    Executive Commentary

    Michael S. Poirier, QLGN Chairman, CEO, and President, while commenting on the results said that the company is encouraged by what it believes to be a strong quarter, as there was a 38% year-over-year increase in revenue. He further said that the company would continue to be encouraged by this increase. He hoped that the developments in the therapeutics business would start paying the company more dividends in long run soon.

    Publication Validating FastPack® IP Diagnostics Test

    On 19th October, QLGN announced the publication of a study in the peer-reviewed journal, by the name of Diagnostics. The publication validated the Company’s point of care FastPack® IP diagnostics test as compared to a laboratory method that determined thyroid-stimulating hormone (TSH) levels in the blood. The study provided validation behind the evidence which supported the reliability of FastPack compared to laboratory tests.

    Future Outlook for QLGN

    Statistics reveal that during the last 12 months, QLGN stock has declined more than 50%. But keeping in view the more recent times, it appears that that stock is leaping forward, even though slowly. Analysts believe that QLGN stock’s recent performance could impart a significant influence upon potential investors to make investments in Qualigen.

  • Qualigen Therapeutics, Inc. (QLGN) Stock on the Rise Following IND Submission for Novel Covid-19 Treatment, QN-165

    Qualigen Therapeutics, Inc. (QLGN) stock prices were up 1.6854% as of the market opening on July 14th, 2021, with premarket trading having seen the stock rise sharply. As of writing, the price per share of QLGN stock was USD$1.81.

    IND Submission

    July 14th, 2021 saw the biotechnology company announce the submission of an Investigational New Drug Application to the U.S Food and Drug Administration with an initial target indication for the treatment of hospitalized Covid-19 patients with the company’s QN-165. The DNA aptamer is a broad-based antiviral drug candidate that has shown antiviral activity in various in vitro assays against a plethora of viruses.

    Milestone for QLGN

    The significant milestone is the first IND application submitted by the company for its most advanced therapeutics program. The IND application submission for Phase 1b/2a clinical trials for QN-165 represents another step in the company’s evolution from a globally patented and commercially successful diagnostics company to a clinical-stage therapeutics company with multiple programs.

    QN-165

    QN-165 is a unique drug candidate that presents an entirely novel approach to combating viruses, which the company thinks it will be able to work against all virus strains and variants. The treatment is a piece of synthetic DNA that does not target the coronavirus directly, as existing treatments do. Rather, it targets and binds to the nucleolin protein and has the capacity to enter cells that overexpress nucleolin. Nucleolin is exploited by viruses such as Covid-19 to gain access to a cell, manipulating it for its own viral replication purposes.

    Scope of QN-165

    By tying up nucleolin, QN-165 is anticipated to block the mechanism entirely, thus preventing the virus replication process. Because of this, even the mutation of the virus is not expected to result in a loss of efficacy of the treatment, on account of nucleolin being targeted instead of the virus itself. This is what the company believes will make the treatment effective against a plethora of viral mutations, including all strains and variants of the novel coronavirus.

    Future Outlook for QLGN

    With the world hurtling towards global immunizations, the onslaught of variants and strains that pop up across the globe are becoming an increasingly significant concern. Treatments such as QN-165 are set to address those concerns, thereby signaling the massive potential for commercialization and proliferation of the expansive market. Investors are hopeful that management will leverage its resources to deliver the treatment as quickly as possible, thus ensuring maximum increases in shareholder value.

  • Qualigen Therapeutics, Inc. (QLGN) fell in the after-hours trading session; here’s why

    Qualigen Therapeutics, Inc. (QLGN) fell in the after-hours trading session; here’s why

    QLGN stock had plunged -18.08% to trade at $2.13 in the after-market at the time of writing. QLGN stock closed the Friday trading session at $2.60 which was 0.76% lower. The volume of trade was 0.48 million shares which was lower than the average daily volume of 1.49 million for the past 50 days.

    What is recent activity of QLGN stock

    The biotech company has been operationally active in the month of March through engaging in conferences, making administrative changes and advances, as well as the acquisition of new biotech technologies.

    On March 9th, the QLGN stock announced that it has a newly gained Chief Financial Officer for Qualigen’s corporate headquarters in Carlsbad, California. The company promoted ShishirSinha to CFO who has been valuable to the company for the past 15 years.

    The company also took part in the presentation at the Oppenheimer 31st Annual Healthcare Conference from 16-18th March. The conference would provide investors a broad spectrum of all the public and private healthcare companies in the health industries of various specialties and niches.

    On 1st March, QLGN announced that it was looking into an entered agreement known as Material Evaluation and Option Agreement with the University College of London. The agreement purpose is to seek options of advancing the commercial expansion of drug candidate ALAN AS1411-GNP. The agreement is known as Material Evaluation and Option Agreement.

    Core operational focus of QLGN stock

    Currently, Qualigen Therapeutics is focusing on maintaining and expanding its core FastPack® system that has been approved by the Food and Drug Administration. The system is also ISO-certified and sold across the globe through a commercial partnership with Sekisui Diagnostics, LLC. FastPack® system has helped physicians, medical clinics, and hospitals in providing efficiency in diagnostic procedures. The system comes in the form of diagnostic instruments and test kits. The FastPack System specifically focuses on rapid point-of-care diagnostic tests for cancer, as well as men’s health, hormone functions, and vitamin D status. Since the pandemic has struck, FastPack® also provides quick and efficient diagnostics of anti –bodies against SARS-CoV-2.

    Background into the Company

    Qualigen therapeutics is a biotechnology company based in Carlsbad, California. It aims to focus on the design and production of new therapies that are novel treatment, innovative in nature.  These treatments are specifically being clinically experimented and bio-engineered to focus on cancer and infectious diseases.

    The Qualigen Therapeutic has cancer therapeutics as candidates that are still going through the development stage. The pipeline of QLGN stock includes three candidates which are ALAN (AS1411-GNP), RAS-F and STARSTM.

    ALAN (AS1411-GNP) is a cancer drug candidate that has its DNA coated in gold nanoparticles. The uniqueness of this drug is that in can target numerous cancer types and does it with minimal side effects. The base of the drug is the nucleolin-targeting DNA aptamer. The foundational DNA aptamer is also an experimental candidate that is used for the treatment of viral-based infections as well as COVID-19.

    STARS is also a DNA/RNA based treatment which a device that is also in the candidate stage. The purpose of this device is to remove the targeted tumor and viral compounds in the blood circulation.

    RAS-F belongs to the family of RAS oncongene protein-protein interaction inhibitor small molecules. This family of RAS molecules is used for the prevention of mutated RAS genes’ proteins from binding in their effector proteins. Prevention of this binding allows for the stoppage of tumor growth process. This is effective especially in the lung cancer, pancreatic and colorectal cancers.

  • What changed for these 49 stocks in Pre-Market Session?

    What changed for these 49 stocks in Pre-Market Session?

    Fuel Tech Inc. (FTEK) stock plunged -8.8% to $1.14 in the pre-market trading after the technology company offered advanced engineering solutions for the optimization of combustion, pollution control, and water treatment systems in utility and industrial applications, financial results for the third quarter were officially published. The most recent rating by H.C. Wainwright, on March 13, 2020, is at a Neutral.

    Equillium Inc. (NASDAQ: EQ) shares are trading down -4.17% at $4.83 at the time of writing after on November 11, the company announced quarterly results for the third quarter of 2020. The company’s 52-week range was noted as $2.20 to $27.05. Analysts have a consensus price target of $24.

    Immuron Limited (IMRN) tumbled over -4.17% at $8.05 in pre-market trading today. US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine.

    Infinity Pharmaceuticals Inc. (INFI), a Biotechnology company, dropped about -6.62% at $1.41 in pre-market trading Thursday following an earnings surprise of -6.67 percent was revealed by the company. It was anticipated a quarter ago that this drugmaker would report a loss of $0.20 per share when it actually posted a $0.16 loss, providing a 20 percent surprise.
    .

    Tellurian Inc. (TELL) stock moved down -5.6 percent to $1.18 in the pre-market trading following the company finished the third quarter of 2020, with cash and cash equivalents of roughly $77.9 million and current borrowings of about $80.8 million. The balance sheet of Tellurian accounted for about $293.3 million in total assets.

    Co-Diagnostics Inc. (CODX) gained over 5.19% at $13.99 in pre-market trading Thursday 12 November 2020. Co-Diagnostics, Inc. CoPrimers™ Shown to be Effective in COVID-19 Saliva PCR Tests Without Sample Extraction.

    Abeona Therapeutics Inc. (ABEO) is down more than -3.85% at $1.25 in pre-market hours Thursday 12 November 2020 after a front-runner in gene and cell therapy, revealed quarterly results and business updates. The stock had jumped over 13.04% to $1.30 in the last trading session.

    Before the trading started on 12 November 2020, MannKind Corporation (MNKD) is down -3.57% to reach $2.7. It has been trading in a 52-week range of $0.80 to $2.52.

    RAVE Restaurant Group Inc. (RAVE) stock plunged -11.84% to $0.67 in the pre-market trading. The most recent rating by ROTH Capital, on May 12, 2016, is at a Neutral.

    Dada Nexus Limited (NASDAQ: DADA) shares are trading up 5.08% at $32.7 at the time of writing. The company’s 52-week range was noted as $14.60 to $37.38. Analysts have a consensus price target of $36.

    FuelCell Energy Inc. (FCEL) tumbled over -1.49% at $2.65 in pre-market trading today.

    Zoom Video Communications Inc. (ZM), a Telecom Services company, rose about 3.38% at $427.3 in pre-market trading Thursday.

    Canaan Inc. (CAN) stock moved up 3.05 percent to $2.7 in the pre-market trading.

    Muscle Maker Inc. (GRIL) lost over -9.6% at $1.79 in pre-market trading Thursday 12 November 2020.

    Moderna Inc. (MRNA) is up more than 5.03% at $86.59 in pre-market hours Thursday 12 November 2020. The stock had jumped over 8.40% to $82.44 in the last trading session. Moderna Has Completed Case Accrual for First Planned Interim Analysis of its mRNA Vaccine Against COVID-19 (mRNA-1273).

    Before the trading started on 12 November 2020, Coty Inc. (COTY) is down -3.89% to reach $4.45 after the company topped analysts’ outlook and surged as much as 22.2% on Nov 6 following its first-quarter fiscal 2021 results. It has been trading in a 52-week range of $2.65 to $13.01.

    Pinduoduo Inc. (PDD) stock soared 17.53% to $131.0 in the pre-market trading following an innovative and emerging tech firm and one of the top Chinese e-commerce players, revealed its unaudited financial results for the third quarter ended September 30, 2020. The most recent rating by Goldman, on November 03, 2020, is a Buy.

    Sea Limited (NYSE: SE) shares are trading up 3.48% at $175.01 at the time of writing following the news recently that pharmaceutical companies are closing on their COVID-19 vaccine candidates. The company’s 52-week range was noted as $30.50 to $187.75. Analysts have a consensus price target of $164.

    GrowGeneration Corp. (GRWG) grew over 7.26% at $22.46 in pre-market trading today after GrowGeneration reported record third-quarter 2020 Financial Results.

    Blink Charging Co. (BLNK), a Specialty Retail company, rose about 5.09% at $10.73 in pre-market trading Thursday.

    LightInTheBox Holding Co. Ltd. (LITB) stock moved up 3.31 percent to $2.5 in the pre-market trading.

    Bionano Genomics Inc. (BNGO) gained over 14.13% at $0.639 in pre-market trading Thursday 12 November 2020. Multi-Center Evaluation of Bionano Optical Genome Mapping by Cytogenetics Thought Leaders in the US Leads to Recommendation for Bionano’s Saphyr to Replace Karyotyping as First-Line Test for Detection and Identification of Structural and Copy Number Variants in Leukemia Patients.

    Vroom Inc. (VRM) is down more than -9.88% at $36.77 in pre-market hours Thursday 12 November 2020 following Vroom reported third Quarter 2020 results. The stock had jumped over 6.56% to $40.80 in the last trading session.

    Before the trading started on 12 November 2020, Turkcell Iletisim Hizmetleri A.S. (TKC) is up 3.16% to reach $5.23. It has been trading in a 52-week range of $4.36 to $6.36.

    Himax Technologies Inc. (HIMX) stock soared 12.2% to $4.6 in the pre-market trading after the prediction of Revenue to surge by approx. 10% consecutively and Gross Margin to get close to 29%. The most recent rating by Credit Suisse, on April 01, 2020, is at an Outperform.

    Qualigen Therapeutics Inc. (NASDAQ: QLGN) shares are trading down -10.03% at $3.23 at the time of writing. The company’s 52-week range was noted as $3.29 to $21.50.

    NovaBay Pharmaceuticals Inc. (NBY) grew over 8.82% at $0.67 in pre-market trading today.

    IMAC Holdings Inc. (IMAC), a Medical Care Facilities company, rose about 146.1% at $2.05 in pre-market trading Thursday. IMAC Holdings, Inc. Expands Missouri Footprint with Acquisition of Lockwood Chiropractic in Webster Groves.

    Sino-Global Shipping America Ltd. (SINO) stock moved up 62.18 percent to $3.13 in the pre-market trading.

    InVivo Therapeutics Holdings Corp. (NVIV) lost over -3.21% at $0.555 in pre-market trading Thursday 12 November 2020.

    Castor Maritime Inc. (CTRM) is up more than 18.5% at $0.1595 in pre-market hours Thursday 12 November 2020 after the company posted fiscal Results for the Three Months and Nine Months Ended September 30, 2020. The stock had jumped over 4.95% to $0.13 in the last trading session.

    Before the trading started on 12 November 2020, Just Energy Group Inc. (JE) is down -13.28% to reach $5.29 as a retail energy provider specializing in electricity and natural gas commodities, revealed its quarterly results for the fiscal year 2021. It has been trading in a 52-week range of $4.27 to $93.72.

    OraSure Technologies Inc. (OSUR) stock soared 4.55% to $14.02 in pre-market trading after the company recently topped its 3rd quarter fiscal earnings predictions. The most recent rating by Evercore ISI, on August 21, 2020, is at an Outperform.

    Riot Blockchain Inc. (NASDAQ: RIOT) shares are trading up 4.17% at $3.75 at the time of writing after the news that Bitcoin might take off again after a big gap. The company’s 52-week range was noted as $0.51 to $4.58.

    NortonLifeLock Inc. (NLOK) tumbled over -7.02% at $18.68 in pre-market trading today despite the earnings beat in the recent week.

    NIO Limited (NIO), an Auto Manufacturers company, rose about 3.41% at $44.55 in pre-market trading Thursday after the analyst’s prediction that NIO can be the main player in the Electric Vehicle market.

    JD.com Inc. (JD) stock moved up 5.38 percent to $87.3 in the pre-market trading following the news that JD.com was the largest US seller in China on Singles day.

    Kandi Technologies Group Inc. (KNDI) gained over 8.84% at $6.77 in pre-market trading Thursday 12 November 2020 despite its disappointing sales results in the financial 3rd quarter of this year.

    ICL Group Ltd (ICL) is up more than 3.11% at $3.98 in pre-market hours Thursday 12 November 2020 as the company topped analysts’ outlook on every front. The stock had jumped over 3.21% to $3.86 in the last trading session.

    Before the trading started on 12 November 2020, Uxin Limited (UXIN) is down -3.81% to reach $1.01 after the news that the company’s proprietary rating system has been introduced that assesses and determines the quality of a used vehicle, offers greater precision to make the decision-making process simpler for consumers and enhances the overall consumer experience. The stock has been trading in a 52-week range of $0.72 to $3.30.

    Baozun Inc. (BZUN) stock soared 3.07% to $40.57 in pre-market trading after the news that the stock still carries a great potential for investors. The most recent rating by Credit Suisse, on June 03, 2020, is at an Outperform.

    XpresSpa Group Inc. (NASDAQ: XSPA) shares are trading up 4.47% at $1.87 at the time of writing after the news that the firm to offer Business Update and will reveal Third Quarter 2020 Financial Results on November 16, 2020. The company’s 52-week range was noted as $0.15 to $8.82.

    KE Holdings Inc. (BEKE) grew over 3.48% at $72.02 in pre-market trading today after the news that the company will announce its quarterly report on November 16, 2020.

    Revolve Group Inc. (RVLV), an Internet Retail company, dropped about -8.96% at $20.43 in pre-market trading Thursday after the company Announced Third Quarter 2020 Financial Results with topping all analysts predictions.
    .

    American Tower Corporation (REIT) (AMT) stock moved up 2.75 percent to $245.0 in the pre-market trading after the reports that the company took over InSite Wireless Group for USD 3.5 billion.

    BIO-key International Inc. (BKYI) gained over 16.2% at $0.52 in pre-market trading Thursday 12 November 2020.

    Liminal BioSciences Inc. (LMNL) is up more than 11.19% at $4.57 in pre-market hours Thursday 12 November 2020 after the report that the firm will reschedule its announcement of quarterly results and conference call. The stock had jumped over 2.49% to $4.11 in the last trading session.

    Before the trading started on 12 November 2020, GoHealth Inc. (GOCO) is down -4.5% to reach $12.73. It has been trading in a 52-week range of $10.02 to $26.25.

    XPeng Inc. (XPEV) stock soared 10.53% to $37.06 in pre-market trading after the company unveiled upbeat quarterly results. The most recent rating by Citigroup, on November 04, 2020, is a Buy.